Clinical Trial

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2 single arm study to evaluate efficacy and safety of Pembrolizumab before with BEAM ASCT followed by Pembrolizumab maintenance for 1 year. Patients will receive 200 mg Pembrolizumab Q3week starting at day - 28 before stem cell transplant until 1 year after autologous stem cell transplant.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-04-17; most recent amendment 2026-07-02.
Status change: Not Yet Recruiting → Recruiting 2025-01-02
Trial Details
NCT Number NCT06377540
Lead Sponsor Masonic Cancer Center, University of Minnesota
Conditions Autologous Stem Cell Transplant, Classic Hodgkin Lymphoma
Enrollment 28 participants
Start Date 2024-12-04
Primary Completion 2026-09-01 (estimated)
Study Completion 2027-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-06